Seasonal influenza vaccination among people with diabetes: influence of patients' characteristics and healthcare use on behavioral changes.


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
02 10 2020
Historique:
pubmed: 27 3 2020
medline: 22 6 2021
entrez: 27 3 2020
Statut: ppublish

Résumé

Annual seasonal influenza vaccination (SIV) is recommended for people with diabetes, but vaccine coverage remains low. We estimated the probabilities of stopping or starting SIV, their correlates, and the expected time spent in the vaccinated state over 10 seasons for different patient profiles. We set up a retrospective cohort study of patients with diabetes in 2006 (n = 16,026), identified in a representative sample of beneficiaries of the French National Health Insurance Fund. We followed them up over 10 seasons (2005/06-2015/16). We used a Markov model to estimate transition probabilities and a proportional hazards model to study covariates. Between two consecutive seasons, the probabilities of starting (0.17) or stopping (0.09) SIV were lower than those of remaining vaccinated (0.91) or unvaccinated (0.83). Men, older patients, those with type 1 diabetes, treated diabetes or more comorbidities, frequent contacts with doctors, and with any hospital stay for diabetes or influenza during the last year were more likely to start and/or less likely to stop SIV. The mean expected number of seasons with SIV uptake over 10 seasons (range: 2.6-7.9) was lowest for women <65 years with untreated diabetes and highest for men ≥65 years with type 1 diabetes. Contacts with doctors and some clinical events may play a key role in SIV adoption. Healthcare workers have a crucial role in reducing missed opportunities for SIV. The existence of empirical patient profiles with different patterns of SIV uptake should encourage their use of tailored educational approaches about SIV to address patients' vaccine hesitancy.

Identifiants

pubmed: 32209014
doi: 10.1080/21645515.2020.1729628
pmc: PMC7644174
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2565-2572

Références

Vaccine. 2017 Sep 12;35(38):5095-5101
pubmed: 28807608
Hum Vaccin Immunother. 2019;15(3):732-739
pubmed: 30457421
Hum Vaccin Immunother. 2019;15(1):113-120
pubmed: 30095325
BMC Public Health. 2019 Jul 9;19(1):918
pubmed: 31288768
Vaccine. 2015 Aug 14;33(34):4191-203
pubmed: 25896385
JAMA Pediatr. 2018 May 7;172(5):e180016
pubmed: 29507952
BMC Public Health. 2013 Oct 30;13:1030
pubmed: 24172142
Rev Epidemiol Sante Publique. 2010 Aug;58(4):286-90
pubmed: 20598822
Vaccine. 2015 Jul 9;33(30):3549-55
pubmed: 26044494
Hum Vaccin Immunother. 2018 Jul 3;14(7):1558-1565
pubmed: 29641945
Vaccine. 2019 Oct 16;37(44):6665-6672
pubmed: 31542261
Pharmacoepidemiol Drug Saf. 2017 Apr;26(4):402-411
pubmed: 27910177
Euro Surveill. 2018 Nov;23(48):
pubmed: 30514414
Vaccine. 2018 Nov 29;36(50):7666-7673
pubmed: 30391054
BMC Public Health. 2018 May 2;18(1):569
pubmed: 29716565
Euro Surveill. 2016 Nov 24;21(47):
pubmed: 27918262
Euro Surveill. 2013 Nov 07;18(45):20628
pubmed: 24229790
Clin Microbiol Infect. 2015 Oct;21(10):930.e1-9
pubmed: 26119723
Vaccine. 2020 Jan 29;38(5):1144-1151
pubmed: 31810781
BMC Public Health. 2013 Apr 25;13:388
pubmed: 23617788
Vaccine. 2017 Jan 3;35(1):101-108
pubmed: 27890398
Cochrane Database Syst Rev. 2018 May 30;5:CD005188
pubmed: 29845606
Vaccine. 2018 May 31;36(23):3351-3358
pubmed: 29716777
Hum Vaccin. 2008 May-Jun;4(3):229-33
pubmed: 18414061
Euro Surveill. 2018 Apr;23(17):
pubmed: 29717693
Int J Environ Res Public Health. 2019 Jun 12;16(12):
pubmed: 31212739
J Med Internet Res. 2017 Sep 06;19(9):e312
pubmed: 28877862
Vaccine. 2019 Feb 8;37(7):984-990
pubmed: 30655175
Vaccine. 2019 Oct 31;37(46):6900-6906
pubmed: 31564452
Hum Vaccin Immunother. 2018 Mar 4;14(3):693-698
pubmed: 28922083
BMC Fam Pract. 2012 Jul 09;13:56
pubmed: 22697490
BMJ. 2013 Aug 23;347:f5061
pubmed: 23974637
Eur J Public Health. 2012 Aug;22(4):562-8
pubmed: 21750011

Auteurs

A Bocquier (A)

Aix Marseille Univ, IRD, AP-HM, SSA, VITROME , Marseille, France.
IHU-Méditerranée Infection , Marseille, France.
ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur , Marseille, France.

S Cortaredona (S)

Aix Marseille Univ, IRD, AP-HM, SSA, VITROME , Marseille, France.
IHU-Méditerranée Infection , Marseille, France.

L Fressard (L)

Aix Marseille Univ, IRD, AP-HM, SSA, VITROME , Marseille, France.
IHU-Méditerranée Infection , Marseille, France.
ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur , Marseille, France.

F Galtier (F)

INSERM, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-Reivac), GH Cochin Broca Hôtel Dieu , Paris, France.
CIC 1411, CHU Montpellier, Hôpital Saint Eloi , Montpellier, France.

P Verger (P)

Aix Marseille Univ, IRD, AP-HM, SSA, VITROME , Marseille, France.
IHU-Méditerranée Infection , Marseille, France.
ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur , Marseille, France.
INSERM, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-Reivac), GH Cochin Broca Hôtel Dieu , Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH